Key Points
- Director Phillip Md Et Al Frost purchased 50,000 shares of Cocrystal Pharma on December 31 at an average price of $0.95, bringing his direct holdings to 1,838,551 shares (about a 2.8% increase, valued near $1.75M).
- Frost accumulated a total of 159,000 shares in multiple buys from November 25 to December 31 at roughly $0.94–$0.99 per share, indicating continued insider buying in the microcap company (market cap ≈ $13.68 million); analysts’ consensus is a Hold with a $6 price target but mixed ratings.
Cocrystal Pharma, Inc. (NASDAQ:COCP - Get Free Report) Director Phillip Md Et Al Frost purchased 50,000 shares of the firm's stock in a transaction dated Wednesday, December 31st. The shares were acquired at an average cost of $0.95 per share, with a total value of $47,500.00. Following the completion of the purchase, the director directly owned 1,838,551 shares in the company, valued at approximately $1,746,623.45. This represents a 2.80% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Tuesday, December 30th, Phillip Md Et Al Frost bought 20,000 shares of Cocrystal Pharma stock. The shares were acquired at an average price of $0.97 per share, with a total value of $19,400.00.
- On Friday, December 26th, Phillip Md Et Al Frost bought 40,000 shares of Cocrystal Pharma stock. The stock was acquired at an average cost of $0.97 per share, with a total value of $38,800.00.
- On Wednesday, December 24th, Phillip Md Et Al Frost purchased 25,000 shares of Cocrystal Pharma stock. The shares were acquired at an average cost of $0.97 per share, for a total transaction of $24,250.00.
- On Wednesday, November 26th, Phillip Md Et Al Frost acquired 4,000 shares of Cocrystal Pharma stock. The shares were acquired at an average price of $0.99 per share, with a total value of $3,960.00.
- On Tuesday, November 25th, Phillip Md Et Al Frost bought 20,000 shares of Cocrystal Pharma stock. The stock was purchased at an average cost of $0.94 per share, with a total value of $18,800.00.
Cocrystal Pharma Stock Performance
Cocrystal Pharma stock opened at $0.99 on Friday. The stock has a 50-day simple moving average of $1.02 and a 200 day simple moving average of $1.31. The stock has a market capitalization of $13.68 million, a P/E ratio of -1.06 and a beta of 1.13. Cocrystal Pharma, Inc. has a 52 week low of $0.90 and a 52 week high of $2.67.
Cocrystal Pharma (NASDAQ:COCP - Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.03. Research analysts forecast that Cocrystal Pharma, Inc. will post -1.85 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Cocrystal Pharma has a consensus rating of "Hold" and a consensus price target of $6.00.
View Our Latest Research Report on COCP
About Cocrystal Pharma
(
Get Free Report)
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company's pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
